Largest childhood preventative health initiative in nearly 20 yearsBeyfortus rollout to ensure all babies are RSV protected this winterThe largest ...

Sanofi's Qfitlia gains FDA approval, offering fewer injections in hemophilia care. Check out my recommendation for SNY stock.

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

For the first time, RSV immunisation is now available to Western Australians both during pregnancy, and for eligible babies ...

Learn more about whether AstraZeneca PLC or Corcept Therapeutics Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In its first full year, Dupixent made almost €13 billion, while Beyfortus, a new RSV vaccine for infants, made €1.7 billion and became a blockbuster. Despite a 1.8% drop in reported terms ...

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The panel voted 21 to zero that Beyfortus (nirsevimab) appears to be safe and effective at preventing RSV infections in newborns and infants as they face their first RSV season, setting the drug ...

It believes that its three new products launched/added in 2023, Altuviiio (for hemophilia A), Beyfortus (for RSV) and Tzield (for type 1 diabetes), together can add up to at least €5 billion in ...

Upcoming market catalysts for the second quarter of 2025 include the US approval decisions for clesrovimab (MK-1654) for respiratory syncytial virus (RSV) prophylaxis, sebetralstat for hereditary ...